GENES CHROMOSOMES & CANCER

Scope & Guideline

Decoding Cancer: The Genetic Connection.

Introduction

Explore the comprehensive scope of GENES CHROMOSOMES & CANCER through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore GENES CHROMOSOMES & CANCER in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN1045-2257
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1989 to 2024
AbbreviationGENE CHROMOSOME CANC / Gene Chromosomes Cancer
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal "Genes Chromosomes & Cancer" focuses on the interplay between genetic alterations and cancer development, providing a platform for research that elucidates the molecular mechanisms driving malignancies. Its scope encompasses a wide range of studies, from genetic and epigenetic modifications to chromosomal aberrations and their implications in cancer pathology and treatment.
  1. Genetic Alterations in Cancer:
    The journal emphasizes the role of genetic mutations, fusions, and other alterations in the development and progression of various cancers, including sarcomas, leukemias, and solid tumors.
  2. Molecular Characterization of Tumors:
    Research published in the journal often includes comprehensive molecular profiling of tumors, utilizing techniques such as whole-genome sequencing, transcriptome analysis, and targeted gene panels to identify novel genetic alterations.
  3. Tumor Microenvironment and Its Impact:
    The journal explores the interactions between tumor cells and their microenvironment, highlighting how these relationships can influence tumor behavior, treatment response, and patient outcomes.
  4. Clinical Implications of Genetic Findings:
    A significant focus is placed on the clinical relevance of genetic findings, including their potential for precision medicine, prognostic value, and implications for targeted therapies.
  5. Innovative Diagnostic Approaches:
    The journal encourages studies that develop new diagnostic methodologies, such as machine learning applications in pathology, to improve cancer detection and classification.
The journal "Genes Chromosomes & Cancer" has reflected several emerging trends and themes in the field of cancer research, particularly those driven by advances in genomic technologies and a deeper understanding of cancer biology. These trends highlight the journal's commitment to cutting-edge research that is relevant to contemporary challenges in oncology.
  1. Gene Fusion Discovery:
    Recent publications highlight an increasing focus on identifying novel gene fusions across various cancer types, particularly in sarcomas, which are crucial for diagnosis and targeted therapy.
  2. Precision Medicine and Targeted Therapies:
    There is a growing trend towards research that emphasizes precision medicine, with studies exploring the therapeutic implications of specific genetic alterations and the development of targeted treatments.
  3. Integration of Multi-Omics Approaches:
    The use of multi-omics strategies that combine genomic, transcriptomic, and epigenomic data to provide comprehensive insights into tumor biology is on the rise, reflecting a trend towards holistic cancer research.
  4. Tumor Microenvironment Interactions:
    Emerging themes include the study of tumor microenvironment interactions and their effects on tumor progression and treatment responses, highlighting the complexity of cancer biology.
  5. Artificial Intelligence in Cancer Research:
    The incorporation of artificial intelligence and machine learning in cancer diagnostics and prognostication is increasingly prevalent, marking a significant shift towards computational approaches in oncology.

Declining or Waning

While the journal continues to publish a variety of impactful research, certain themes that were once prominent are becoming less frequent in recent publications. This shift may reflect evolving interests in the cancer research community or advances in technology that have rendered certain approaches less relevant.
  1. Traditional Cytogenetic Techniques:
    There is a noticeable decline in studies focusing on conventional cytogenetic techniques, such as karyotyping, as newer genomic technologies like next-generation sequencing gain prominence.
  2. Generalized Cancer Epidemiology Studies:
    Research that broadly examines cancer incidence and prevalence without a strong genetic or molecular focus appears to be waning, as the field shifts towards more targeted and mechanistic investigations.
  3. Non-Genetic Factors in Cancer:
    While still important, the emphasis on non-genetic factors, such as lifestyle and environmental influences on cancer risk, seems to be decreasing in favor of genetic and molecular research.
  4. Basic Laboratory Studies Without Clinical Correlation:
    There is a trend away from purely laboratory-based studies that do not translate into clinical implications, as the journal increasingly prioritizes research with direct relevance to patient care and treatment.

Similar Journals

Advances in Cancer Biology-Metastasis

Innovating Insights into Cancer Metastasis.
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Molecular Cancer

Transforming cancer knowledge into clinical practice.
Publisher: BMCISSN: Frequency: 1 issue/year

Molecular Cancer, published by BMC, stands as a premier open access journal dedicated to advancing our understanding of cancer biology, treatment, and prevention since its inception in 2002. With an impressive Q1 ranking in the domains of Cancer Research, Molecular Medicine, and Oncology, this journal occupies a significant position in the academic landscape, emphasizing high-quality research that influences clinical practices and future studies. The journal is indexed in leading databases with exceptional Scopus ranks, reflecting its rigorous peer-review process and impactful contributions to the field, where it ranks in the top 2-3 positions across various relevant categories. Based in the United Kingdom, Molecular Cancer offers researchers worldwide a valuable platform for disseminating innovative findings that drive the biomedical community forward. The journal's open access model ensures that groundbreaking research is freely accessible, fostering collaboration and knowledge sharing among professionals, students, and academics alike. Explore cutting-edge developments in cancer research through Molecular Cancer and join a community committed to improving patient outcomes and advancing scientific discovery.

Cancer Cell International

Championing Excellence in Cancer Science
Publisher: BMCISSN: Frequency: 1 issue/year

Cancer Cell International, published by BMC, is a transformative open-access journal established in 2001, dedicated to advancing the field of oncology and cancer research. With its ISSN number not specified and an E-ISSN of 1475-2867, the journal proudly operates from the United Kingdom, located at CAMPUS, 4 Crinan St, London N1 9XW, England. Renowned for its rigorous peer-review process, Cancer Cell International has made significant strides, securing a Q2 ranking in Cancer Research and Q1 rankings in both Genetics and Oncology as of 2023. It ranks impressively in Scopus, featuring in the top quintile of Genetics (#37/347) and Oncology (#52/404), indicating its importance within the scientific community. The journal's broad scope caters to a diverse array of topics within cancer biology, making it an invaluable resource for researchers, professionals, and students seeking to stay at the forefront of cancer science. With a commitment to disseminating high-quality research, Cancer Cell International invites scholars to explore innovative findings and contribute to the collective effort of combating cancer.

CURRENT CANCER DRUG TARGETS

Unveiling novel therapeutic avenues in the fight against cancer.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Illuminating the Pathways of Genetic Change
Publisher: ELSEVIERISSN: 1386-1964Frequency: 12 issues/year

MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.

Cold Spring Harbor Molecular Case Studies

Advancing molecular insights for clinical breakthroughs.
Publisher: COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPTISSN: 2373-2873Frequency: 6 issues/year

Cold Spring Harbor Molecular Case Studies is a prestigious journal published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, that has garnered considerable attention in the fields of Biochemistry, Genetics, and Molecular Medicine. With a focus on the intersection of molecular biology and clinical case studies, this journal serves as a key resource for researchers and practitioners seeking to explore novel insights into genetic disorders and biomedical advances. Its impact is underscored by its categorization in Q2 in various disciplines in 2023, reflecting its significance and influence within the academic community. Although currently not labeled as Open Access, Cold Spring Harbor Molecular Case Studies provides a rigorous platform for disseminating high-quality, peer-reviewed research that drives innovation and enhances understanding in these rapidly evolving fields. As a supporter of advancing scientific knowledge, this journal is essential for those dedicated to the exploration of molecular mechanisms and their clinical implications.

JOURNAL OF GENE MEDICINE

Innovating Molecular Medicine for Tomorrow
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Cancer Genomics & Proteomics

Transforming cancer studies through high-quality research insights.
Publisher: INT INST ANTICANCER RESEARCHISSN: 1109-6535Frequency: 6 issues/year

Cancer Genomics & Proteomics is a pivotal journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of cancer genomics and proteomics. Established in 2004 and running until 2024, this journal provides a vital platform for the dissemination of high-quality research that explores genetic and protein interactions in cancer, thereby fostering innovations in diagnostics and therapeutics. The journal boasts a commendable Q2 ranking in Biochemistry and Genetics and is recognized in the Q3 tier for its contributions to Cancer Research and Molecular Biology, reflecting its growing impact in these dynamic fields. Operating out of Greece, it engages a diverse audience, including researchers, clinicians, and students, by sharing significant findings and methodological advancements in the realm of cancer studies. While currently not an open-access publication, Cancer Genomics & Proteomics remains committed to enriching scientific dialogue and collaboration with its insightful articles and reviews.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Unraveling the Complexities of Cancer Biology
Publisher: ELSEVIERISSN: 0304-419XFrequency: 4 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, published by Elsevier, has established itself as a leading journal in the domains of cancer research, genetics, and oncology, holding a prestigious position in the Q1 quartile rankings in these fields as of 2023. With an ISSN of 0304-419X and an E-ISSN of 1879-2561, this journal aims to disseminate high-quality, impactful reviews that synthesize the latest advancements and findings in cancer biology, treatment modalities, and genomic studies. Its robust indexing and remarkable Scopus rankings—placing it in the 95th to 91st percentiles across various categories—underline its significance for researchers, clinicians, and students passionate about oncology. Operating from its Netherlands headquarters, BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER is dedicated to fostering a comprehensive understanding of the complex biological mechanisms underlying cancer, promoting innovative therapeutic strategies, and guiding future research directions.

Genes & Diseases

Shedding light on the genetic foundations of disease.
Publisher: KEAI PUBLISHING LTDISSN: 2352-4820Frequency: 6 issues/year

Genes & Diseases, published by KEAI PUBLISHING LTD, is a premier open-access journal dedicated to advancing the fields of genetics, biochemistry, and molecular biology. Established in 2014 and headquartered in Beijing, China, this journal has quickly risen to prominence, securing a place in the prestigious Q1 quartile in Biochemistry and Genetics (clinical), as well as Q2 in Cell Biology and Q1 in Molecular Biology as of 2023. With a commitment to disseminating cutting-edge research, Genes & Diseases serves as a critical platform for researchers, professionals, and students alike, ensuring that high-quality scientific work is openly accessible to the global community. The journal's exceptional impact is underscored by its selective Scopus rankings, which reflect its influence and relevance in key scientific domains, making it an essential resource for those exploring the intersections of genetics and disease pathology.